Aperio Group LLC boosted its stake in Balchem Co. (NASDAQ:BCPC) by 11.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,776 shares of the basic materials company’s stock after buying an additional 1,566 shares during the period. Aperio Group LLC’s holdings in Balchem were worth $1,768,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of BCPC. Zeke Capital Advisors LLC purchased a new stake in Balchem in the 2nd quarter valued at about $203,000. Cubist Systematic Strategies LLC purchased a new stake in Balchem in the 2nd quarter valued at about $218,000. Granahan Investment Management Inc. MA purchased a new stake in Balchem in the 2nd quarter valued at about $224,000. Sigma Planning Corp purchased a new stake in Balchem in the 2nd quarter valued at about $229,000. Finally, CIBC Asset Management Inc purchased a new stake in Balchem in the 2nd quarter valued at about $240,000. Hedge funds and other institutional investors own 88.48% of the company’s stock.
Several analysts recently issued reports on BCPC shares. BidaskClub lowered shares of Balchem from a “strong-buy” rating to a “buy” rating in a report on Friday, July 13th. Pivotal Research boosted their price objective on shares of Balchem from $85.00 to $95.00 and gave the company a “hold” rating in a report on Friday, August 3rd. ValuEngine upgraded shares of Balchem from a “hold” rating to a “buy” rating in a report on Thursday, August 30th. HC Wainwright started coverage on shares of Balchem in a report on Tuesday, September 25th. They issued a “buy” rating on the stock. Finally, Sidoti upgraded shares of Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price objective on the stock in a report on Tuesday, October 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $122.33.
NASDAQ BCPC opened at $90.12 on Friday. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of 35.62 and a beta of 0.97. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.42 and a quick ratio of 2.82. Balchem Co. has a 1-year low of $70.23 and a 1-year high of $117.79.
Balchem (NASDAQ:BCPC) last released its earnings results on Tuesday, November 6th. The basic materials company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.12. The company had revenue of $155.04 million during the quarter, compared to the consensus estimate of $163.66 million. Balchem had a return on equity of 14.51% and a net margin of 15.67%. Balchem’s revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.63 EPS. On average, sell-side analysts forecast that Balchem Co. will post 2.45 earnings per share for the current fiscal year.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Recommended Story: The Role of a Fiduciary and Individual Investors
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.